ImmTOR - Model SEL-212 - Enzymatic Therapy

THE CHALLENGE
Chronic refractory gout is a severe form of inflammatory arthritis characterized by intense inflammation, debilitating pain, and the formation of tophi (painful deposits of urate crystals in joints and soft tissues). The vast majority of patients develop an immune response to the current standard of care and are often forced to discontinue treatment.

These patients are in desperate need of a new, more sustainable treatment option.

SEL-212 DEVELOPMENT
SEL-212 is Selecta’s Phase 3 clinical product candidate in chronic refractory gout, licensed to Sobi in mid 2020. Under the terms of the licensing agreement, Sobi takes on SEL-212 development, regulatory and commercial activities in all markets outside of China.

SEL-212 lays the foundation for Selecta’s pipeline of tolerogenic therapies driven by ImmTOR™

HOW SEL-212 WORKS
SEL-212 is comprised of ImmTOR co-administered with pegadricase, a highly immunogenic enzyme that, when given alone, decreases serum uric acid levels in patients with chronic refractory gout but triggers an immune response to the treatment, as measured by the production of anti-drug antibodies (ADAs).

When ImmTOR™ is co-administered with pegadricase, it has the potential to ameliorate this immune response.